5 Essential Elements For ABBV-744 drug development progress and timeline
In Phase C, individuals will receive ABBV-744 and oral navitoclax. In Section D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment till disease progression or perhaps the contributors are unable to tolerate the study drugs.General, our current work highlights the potential utilization of ARV-825 in combination with TAM.